482 related articles for article (PubMed ID: 7697910)
1. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
[TBL] [Abstract][Full Text] [Related]
2. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
[TBL] [Abstract][Full Text] [Related]
3. Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice.
Fischer W; Schudt C; Wendel A
Biochem Pharmacol; 1993 Jun; 45(12):2399-404. PubMed ID: 8392340
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Badger AM; Olivera DL; Esser KM
Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
6. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
7. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
Pettipher ER; Labasi JM; Salter ED; Stam EJ; Cheng JB; Griffiths RJ
Br J Pharmacol; 1996 Apr; 117(7):1530-4. PubMed ID: 8730750
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
[TBL] [Abstract][Full Text] [Related]
9. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation.
Sekut L; Menius JA; Brackeen MF; Connolly KM
J Lab Clin Med; 1994 Dec; 124(6):813-20. PubMed ID: 7798795
[TBL] [Abstract][Full Text] [Related]
11. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
13. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
Schade FU; Schudt C
Eur J Pharmacol; 1993 Jan; 230(1):9-14. PubMed ID: 8381357
[TBL] [Abstract][Full Text] [Related]
14. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig.
Turner NC; Dolan JS; Grimsditch D; Lamb J; Worby A; Murray KJ; Coates WJ; Warrington BH
Br J Pharmacol; 1994 Apr; 111(4):1198-204. PubMed ID: 8032606
[TBL] [Abstract][Full Text] [Related]
16. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
[TBL] [Abstract][Full Text] [Related]
17. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent.
Haskó G; Szabó C; Németh ZH; Salzman AL; Vizi ES
Eur J Immunol; 1998 Feb; 28(2):468-72. PubMed ID: 9521054
[TBL] [Abstract][Full Text] [Related]
18. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors.
Molnar-Kimber K; Yonno L; Heaslip R; Weichman B
Agents Actions; 1993; 39 Spec No():C77-9. PubMed ID: 8273592
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
Buttini M; Mir A; Appel K; Wiederhold KH; Limonta S; Gebicke-Haerter PJ; Boddeke HW
Br J Pharmacol; 1997 Dec; 122(7):1483-9. PubMed ID: 9421299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
